PT-141
Bremelanotide
Melanocortin receptor agonist with an FDA-approved indication in premenopausal women; other uses discussed with providers.
Starting at$89/month
Provider Determines Testing
Options that may support desire and sexual wellness.
Melanocortin receptor agonist with an FDA-approved indication in premenopausal women; other uses discussed with providers.
Orally active ghrelin receptor agonist studied for GH/IGF-1 secretion.
GHRH and GHRP combination studied for pulsatile growth hormone release.
Neuropeptide sometimes discussed for mood, bonding, and intimacy support in provider-directed protocols.
GHRH analog studied for stimulation of the body's own growth hormone.
GHRH analog with FDA approval for a specific HIV-related indication; sometimes discussed off-label.
Neuroendocrine peptide studied in hypothalamic-pituitary-gonadal signaling.